

A Prospective and Observational Dose Comparative Study of Methotrexate to Evaluate the Quality of Life of Patients with Rheumatoid Arthritis

**Dr. K. Purnachander, B. Anil Kumar, Dr. B. Baburao, Y Akhil,
K. Laharika, T. Ramykrishna G. Saikumar**

Nethaji Institute of Pharmaceutical Sciences, Kazipet, Hanamkonda, Telangana

Abstract: *This Prospective observational dose comparative study was conducted over a period of 6 months in 2019 to identify safety and efficacy of methotrexate in rheumatoid arthritis and quality of life of patients affected with rheumatoid arthritis. The necessary data was collected from the patient case notes, treatment charts, patient attendants. A Total of 300 cases were analysed. From this data we found that majority of the patients were in the age group of 30-50, 70% of patients responded positive for rheumatoid factor, having ESR ranging above 70mmhr, a large group of patients i.e., 99 subjects were observed to have deformities and 97 subjects were having fusion of joints due to inflammation and quality of life of 57.14% patients was compromised due to rheumatoid arthritis. Among 300 subjects of RA quality of life study was conducted and it was found that 57.1% subjects quality of life was compromised due rheumatoid arthritis.*

Keywords: Comparative Study, Arthritis, Inflammation, Quality of Life

REFERENCES

- [1]. Arthritis Foundation. What is Rheumatoid arthritis?
- [2]. Murphy G, Nagase H: Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis destruction or repair? *Nat Clin Pract Rheumatol* 2008, 4:128–135.
- [3]. De Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, Huizinga TW, Kloppenburg M: Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. *Osteoarthritis Cartilage* 2012, 20:1484–1499.
- [4]. Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology (Oxford)* 2012, 51: v3–v11.
- [5]. Firestein GS: Evolving concepts of rheumatoid arthritis. *Nature* 2003, 423:356–361.
- [6]. Isaacs JD: The changing face of rheumatoid arthritis: sustained remission for all? *Nat Rev Immunol* 2010, 10:605–611.
- [7]. Rousseau JC, Delmas PD: Biological markers in osteoarthritis. *Nat Clin Pract Rheumatol* 2007, 3:346–356.
- [8]. Haseeb A, Haqqi TM: Immunopathogenesis of osteoarthritis. *Clin Immunol* 2013, 146:185–196.
- [9]. Reines BP: Is rheumatoid arthritis premature osteoarthritis with fetal-like healing? *Autoimmune Rev* 2004, 3:305–311.
- [10]. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. *Arthritis Res.* 2002;4(4):266–273.
- [11]. Chopra A, Patil J, Billempelly V, Relwani J, Tandle (2001) Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. *J Assoc Physicians India* 49, 240–6. CASpubmed Google Scholar.
- [12]. Pia M. Johnsson, Kerstin Eberhardt *Rheumatology*, volume 48, issue 11, November 2009, pages 1398–1401.